Post-split Abbott announces FDA win for Xience Xpedition stent

January 3, 2013 by MassDevice staff

Healthcare giant Abbott starts off its post-split season with an FDA win for its Xience Xpedition drug-eluting stent system.

Abbott logo

Abbott (NYSE:ABT) announced FDA approval for its Xience Xpedition coronary stent, planning commercial launch in the U.S. immediately.

Abbott's Xience line of drug-eluting stents are the only such devices on the U.S. market approved for "direct stenting," in which the stent is delivered to the targeted blood vessel without a prior procedure preparing the lesion.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp